Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Darolutamide's Role in Treating Nonmetastatic CRPC

December 28th 2017

MFS: A New Endpoint for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: Considerations for Apalutamide

December 28th 2017

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

December 28th 2017

The Value of AR-Targeted Therapy in CRPC

December 28th 2017

Approaching the Treatment of Nonmetastatic CRPC

December 28th 2017

Understanding Nonmetastatic CRPC: An Overview

December 28th 2017

Treating Advanced Bladder Cancer in the Future

December 28th 2017

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

December 28th 2017

Immunotherapy in Second-Line Advanced Bladder Cancer

December 28th 2017

Monitoring for Treatment Response in Advanced Bladder Cancer

December 28th 2017

Frontline Immunotherapy in Advanced Bladder Cancer

December 28th 2017

First-Line Chemotherapy in Advanced Bladder Cancer

December 28th 2017

Advanced Bladder Cancer: Predicting Clinical Response

December 28th 2017

Impact of Immunotherapy in Advanced Bladder Cancer

December 28th 2017

Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

December 22nd 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

FDA Grants Adjuvant Dabrafenib/Trametinib Priority Review for BRAF+ Melanoma

December 22nd 2017

The FDA has granted a priority review to a supplemental new drug application for the use of dabrafenib combined with trametinib as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Gastric/GEJ Cancers: Looking Toward the Future

December 22nd 2017

The Evolving Treatment Landscape in Gastric/GEJ Cancers

December 22nd 2017

Gastric/GEJ Cancers: Non-Immunotherapeutic Advancements

December 22nd 2017